Shapeshifting in Health Care

Cheryl ProvalAs health-care providers tackle the unruly task of managing population health, they are engaging in the mythic—and transformational—practice of changing shapes into different forms. Providers, payors, employers, and even the corner drugstore are swapping roles: opening the door to more competition, but also introducing powerful new partners with which to share the growing burden of patient-care accountability. In the March issue of Health CXO, we hear from the medical director of Walgreens, which is not just dispensing meds, but is playing a growing role in the management of a handful of chronic diseases: diabetes, chronic obstructive pulmonary disease, and HIV. All members of the executive suite are facing new challenges and added responsibilities in the delivery of health care, but CIOs have an especially heavy load: They are managing compliance with a massive new federal health IT program, facilitating clinical and business analytics by harnessing the organization’s big data, and managing what has become a tsunami of interest in mobile access to data. We write about the anytime/anywhere policy at Platte Valley Medical Center (Brighton, Colorado) and a potential new partner in patient-data delivery. We also bring you a Wall Street view of health care from a Citigroup health-research analyst. It’s not pretty, but forewarned is forearmed. How is your organization shapeshifting? Cheryl Provalcproval@healthcxo.com
Cheryl Proval,

Vice President, Executive Editor, Radiology Business

Cheryl began her career in journalism when Wite-Out was a relatively new technology. During the past 16 years, she has covered radiology and followed developments in healthcare policy. She holds a BA in History from the University of Delaware and likes nothing better than a good story, well told.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.